Abstract:Background: Recent studies have identified that transglutaminases (TGMs) are involved in a widespread epigenetic modification in tumorigenesis. However, it remains unclear how transglutaminase 3 (TGM3) affects in pan-cancer. The present study aimed to explore the clinical and prognostic function of TGM3 in pan-cancer as well as to explore the relationship of TGM3 expression with clinical stage, survival rate, prognosis condition, immune infiltration and mutation indicators. Methods: The relevant data of tumors were obtained from The Cancer Genome Atlas (TCGA), TARGET, Cancer Cell Line Encyclopedia (CCLE) and Genotype-Tissue Expression (GTEx) databases. According to the Human Protein Atlas (HPA) and TIMER databases, we evaluated the protein expression levels of TGM3 in different organs and tissues as well as their association with immune cell infiltration and immunotherapeutic response in pan-cancers. Expression differences between normal and tumor tissues as well as survival and prognosis situation, clinical data characteristics, tumor mutational burden (TMB), microsatellite instability (MSI), and RNA methylation were also assessed. Oncogenic analyses were also evaluated by GSEA. Results: Compared to normal tissues, some tumor tissues had a lower expression level of TGM3, while other tumor tissues had a high expression level of TGM3. Further studies showed that high TGM3 expression had a certain risk impact on pan-cancer as high TGM3 expression levels were detrimental to the survival of several cancers, except for pancreatic cancer (PAAD). High expression level of TGM3 was also related to higher clinical stages in most cancers. The expression level of TGM3 was significantly negatively correlated with the expression of immune infiltration-related cells, including B cells, CD8+ T cells, CD4+ T cells, neutrophils, macrophages and dendritic cells (DCs). Furthermore, in most cancer types, TGM3 was inversely correlated with TMB, MSI, and methylation, suggesting that TGM3 expression can be used to assess potential therapeutic response, especially immune-related targeted therapy. GSEA analysis elucidated the biological and molecular function of TGM3 in various cancer types. Taken together, these bioinformatic analyses identified TGM3 as an important biomarker for clinical tumor prognosis and evaluation of treatment efficacy. Conclusion: We comprehensively analyzed the clinical characteristics, tumor stages, immune infiltration, methylation level, gene mutation, functional enrichment analysis and immunotherapeutic value of TGM3 in pan-cancer, providing implications for the function of TGM3 and its role in clinical treatment.

Transglutaminase 3 Protein Modulates Human Esophageal Cancer Cell Growth by Targeting the NF-κB Signaling Pathway.

TGM3 functions as a tumor suppressor by repressing epithelial‑to‑mesenchymal transition and the PI3K/AKT signaling pathway in colorectal cancer.

TGM3 Promotes Epithelial-Mesenchymal Transition and Hepatocellular Carcinogenesis and Predicts Poor Prognosis for Patients after Curative Resection.

TGM3, a Candidate Tumor Suppressor Gene, Contributes to Human Head and Neck Cancer

Clinical and Immunological Characteristics of TGM3 in Pan-Cancer: A Potential Prognostic Biomarker.

Transglutaminase 3 regulates cutaneous squamous carcinoma differentiation and inhibits progression via PI3K-AKT signaling pathway-mediated Keratin 14 degradation

Activation of STAT3 in Human Gastric Cancer Cells Via Interleukin (Il)-6-type Cytokine Signaling Correlates with Clinical Implications

Eif4ebp3 Was Downregulated by Methylation and Acted As a Tumor Suppressor by Targeting Eif4e/β-Catenin in Gastric Cancer.

TPM3 mediates epithelial-mesenchymal transition in esophageal cancer via MMP2/MMP9

Reduced N-acetylglucosaminyltransferase III Expression Via Smad3 and Erk Signaling in TGF-β1-induced HCC EMT Model.

METTL3 promotes the proliferation and invasion of esophageal cancer cells partly through AKT signaling pathway

TAB3 Promotes Human Esophageal Squamous Cell Carcinoma Proliferation and Invasion Via the NF‑κB Pathway.

ESM1 facilitates the EGFR/HER3-triggered epithelial-to-mesenchymal transition and progression of gastric cancer via modulating interplay between Akt and angiopoietin-2 signaling

CMTM3 Decreases EGFR Expression and EGF-mediated Tumorigenicity by Promoting Rab5 Activity in Gastric Cancer.

Eukaryotic translation initiation factor 3B accelerates the progression of esophageal squamous cell carcinoma by activating β-catenin signaling pathway.

High Expression Of Golph3 In Esophageal Squamous Cell Carcinoma Correlates With Poor Prognosis

GGTLC1 Knockdown Inhibits the Progression of Endometrial Cancer by Regulating the TGF-8/Smad Signaling Pathway

Trafficking Protein TMED3 Promotes Esophageal Squamous Cell Carcinoma

TET3 governs malignant behaviors and unfavorable prognosis of esophageal squamous cell carcinoma by activating the PI3K/AKT/GSK3β/β-catenin pathway

Decreased Expression of ATF3, Orchestrated by Β-Catenin/tcf3, Mir-17-5p and HOXA11-AS, Promoted Gastric Cancer Progression Via Increased Β-Catenin and CEMIP

Knockdown of EphB3 Inhibits Cell Proliferation Partly Through the AKT Signaling Pathway and Represses Epithelial-Mesenchymal Transition in Esophageal Squamous Cell Carcinoma